Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
When would you offer nivolumab/relatlimab to a metastatic melanoma patient following progression on BRAF/MEK targeted therapy?
Related Questions
What criteria do you use to determine the resectability of mucosal melanoma of the H&N region?
Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?
Which patients with cSCC could you omit adjuvant radiation following pathologic complete response following cemiplimab?
How would you approach a patient with clinical T3N1 anorectal malignant melanoma referred by a surgeon for neoadjuvant therapy?
What role, if any, do biomarkers play in selecting appropriate patients for neoadjuvant cemiplimab in cutaneous squamous cell carcinoma?
What scenario would flipped dosing versus standard dosing of Ipilimumab+Nivolumab be beneficial in metastatic melanoma?
How do you approach patients with recurrent BRAF negative melanoma and resected oligo-metastasis after completing one year of adjuvant nivolumab?
How do you approach patients with a new primary melanoma, not an in-transit metastasis, while on adjuvant immunotherapy/treatment for a previous melanoma lesion?
What are your top takeaways in Melanoma from ASCO 2022?
Would you consider nivolumab/relatlimab as a salvage therapy option for advanced melanoma patients who progressed on single-agent PD-1 inhibitor?
